(Non-invasive Assessment of Liver Fibrosis)

(fibrosis)

Metavir
systemF2
significant
fibrosis

F4
advanced fibrosis
pre-cirrhosis

(liver biopsy)

(1) (2) (3)

(4)

(5)

(panel)

(AST/ALT)collagenfibronectin

APRI (AST/Platelet Ratio Index)

= AST ( upper limit of normal) 100/
platelet count (109/L) FibroTest
435

 JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2011. vol.19, No.1

APRI

(accuracy) AUROC (area under the

receiver operating characteristic)
F20.78-0.88F4
0. 83- 0. 94 1 , 2

(2-macroglobulinhaptoglobin
-glutamyl transpeptidaseage
bilirubinapolipoprotein A1sex
)FibroTest (Biopredicitve Website:
www.biopredictive.com)
F2AUROC0.85F4
0.87-0.922, 3

4CasteraAPRI
FibroTestF2
0.97F40.88
48.3%74.8%
5

(CT)
(MRI)

(F2)

(Magnetic Resonance Elastography,

MRE)

(Tissue Elastography or
Elastometry, TE)

(Pulse-echo ultrasound)

(Stiffness)
(KPa

436

Castera
TE

F2
0.83F4
0.95
FibroTestTE
F2
0.88F4
0.952

TE 8
TE
6KPa
F1
91%TEF2
0.83F40.90
TEF2
0.88F40.94
TE
100

TE

9 TE

1 pascal=1
)Fibroscan (Echosens,
Paris, France)
(50 Hz)
2.5-6.5

(Figure 1)
4-6 KPa
12-14 KPa 68

(Real-time)TE

(displacement)

(Figure 2.)

F0F1

10

437

 JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2011. vol.19, No.1

-13
(
)

FibroTest
TETE
serum panel TE

3.

4.

5.

References:
1. Wai CT, Greenson JK, Fontana
RJ, Kalbfleisch JD, Marrero JA,
Conjeevaram HS, Lok AS. A simple
noninvasive index can predict both
significant fibrosis and cirrhosis in
patients with chronic hepatitis C.
Hepatology 2003;38:518-26.
2. Castera L, Vergniol J, Foucher J, Le
Bail B, Chanteloup E, Haaser M,
Darriet M, Couzigou P, De Ledinghen
V. Prospective comparison of transient

6.

7.
438

elastography, Fibrotest, APRI, and liver

biopsy for the assessment of fibrosis in
chronic hepatitis C. Gastroenterology
2005;128:343-50.
Imbert-Bismut F, Ratziu V, Pieroni L,
Charlotte F, Benhamou Y, Poynard T.
Biochemical markers of liver fibrosis
in patients with hepatitis C virus
infection: a prospective study. Lancet
2001;357:1069-75.
Sebastiani G, Vario A, Guido M,
Alberti A. Performance of noninvasive
markers for liver fibrosis is reduced
in chronic hepatitis C with normal
transaminases. J Viral Hepat
2008;15:212-8.
Castera L, Sebastiani G, Le Bail B,
de Ledinghen V, Couzigou P, Alberti
A. Prospective comparison of two
algorithms combining non-invasive
methods for staging liver fibrosis
in chronic hepatitis C. J Hepatol
2010;52:191-8.
Ziol M, Handra-Luca A, Kettaneh
A, Christidis C, Mal F, Kazemi
F, de Ledinghen V, Marcellin P,
Dhumeaux D, Trinchet JC, Beaugrand
M. Noninvasive assessment of liver
fibrosis by measurement of stiffness
in patients with chronic hepatitis C.
Hepatology 2005;41:48-54.
Fraquelli M, Rigamonti C, Casazza

G, Conte D, Donato MF, Ronchi

G, Colombo M. Reproducibility of
transient elastography in the evaluation
of liver fibrosis in patients with chronic
liver disease. Gut 2007;56:968-73.
8. Wang JH, Changchien CS, Hung
CH, Eng HL, Tung WC, Kee KM,
Chen CH, Hu TH, Lee CM, Lu SN.
FibroScan and ultrasonography in
the prediction of hepatic fibrosis in
patients with chronic viral hepatitis. J
Gastroenterol 2009;44:439-46.
9. Smith JO, Sterling RK. Systematic

review: non-invasive methods of

fibrosis analysis in chronic hepatitis C.
Aliment Pharmacol Ther 2009;30:55776.
10. Wong GL, Wong VW, Choi PC, Chan
AW, Chum RH, Chan HK, Lau KK,
Chim AM, Yiu KK, Chan FK, Sung
JJ, Chan HL. Assessment of fibrosis
by transient elastography compared
with liver biopsy and morphometry
in chronic liver diseases. Clin
Gastroenterol Hepatol 2008;6:1027-35.

Spider angioma,
Splenomegaly

Platelet, AST,
Alb/TP, AST/ALT

Hyaluronic
acid, collagen,
fibronectin

US, CT, MRI

APRI, ELF,
FPI, Fibotest,
Fibrosp

Methacetin BT,
Aminopyrine BT

439